Immuneering Corporation (NASDAQ:IMRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $17.5714.

A number of research analysts have recently commented on the company. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. Finally, Cantor Fitzgerald began coverage on Immuneering in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 target price for the company.

Immuneering Trading Down 2.4%

Shares of Immuneering stock opened at $4.13 on Friday. The firm’s 50 day moving average is $4.66 and its 200 day moving average is $4.98. The firm has a market capitalization of $267.21 million, a PE ratio of -3.53 and a beta of 0.41. Immuneering has a 1 year low of $2.90 and a 1 year high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09. As a group, research analysts anticipate that Immuneering will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IMRX. Caitong International Asset Management Co. Ltd acquired a new stake in Immuneering during the 4th quarter worth approximately $33,000. Levin Capital Strategies L.P. acquired a new position in Immuneering in the 1st quarter valued at approximately $53,000. Mercer Global Advisors Inc. ADV acquired a new position in Immuneering in the 3rd quarter valued at approximately $70,000. SummitTX Capital L.P. acquired a new position in Immuneering in the 4th quarter valued at approximately $69,000. Finally, Ausdal Financial Partners Inc. bought a new position in shares of Immuneering during the fourth quarter valued at $72,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.